Since vancomycin-intermediate Staphylococcus aureus (VISA) was first reported in Japan in
1997, there has been great concern that heterogeneous vancomycin-intermediate S. aureus …

The first report of Staphylococcus aureus with intermediate-level resistance to vancomycin
(VISA) was from Japan in 1997 (20), raising the threat of incurable staphylococcal infections …

We screened 533 and 361 methicillin (meticillin)-resistant Staphylococcus aureus strains
isolated in a university hospital in 2002 and 2003 and in 2006 and 2007, respectively, and …

In addition to vancomycin-intermediate Staphylococcus aureus (VISA), S. aureus with a
vancomycin MIC of 4 µ g/ml has been reported to be the cause of therapeutic failure. This …

Abstract The Clinical and Laboratory Standards Institute (CLSI) amended the criteria for
vancomycin susceptibility and resistance of Staphylococcus aureus in 2006. The earlier …

In 1999, all clinical Staphylococcus aureus isolates from patients admitted to a Belgian
University hospital were tested for decreased vancomycin susceptibility. Three vancomycin …

Objectives: We investigated vancomycin-intermediate Staphylococcus aureus (VISA) and
heterogeneously vancomycin-intermediate S. aureus (hetero-VISA) isolates from clinical …

We investigated the prevalence and the molecular characteristics of vancomycin-
intermediate Staphylococcus aureus (VISA) among methicillin-resistant Staphylococcus …

Methicillin-resistant Staphylococcus aureus (MRSA) accounts for more than 70% of S.
aureus isolates from tertiary hospitals in Korea. Clinical isolates of S. aureus were collected …

Vancomycin-intermediate Staphylococcus aureus (VISA) are an emerging problem. We
observed a statistically significant inverse relationship in the MICs of vancomycin and …